Literature DB >> 18537267

Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.

Amy R Hurshman Babbes1, Evan T Powers, Jeffery W Kelly.   

Abstract

Urea denaturation studies were carried out as a function of transthyretin (TTR) concentration to quantify the thermodynamically linked quaternary and tertiary structural stability and to improve our understanding of the relationship between mutant folding energetics and amyloid disease phenotype. Urea denaturation of TTR involves at least two equilibria: dissociation of tetramers into folded monomers and monomer unfolding. To deal with the thermodynamic linkage of these equilibria, we analyzed concentration-dependent denaturation data by globally fitting them to an equation that simultaneously accounts for the two-step denaturation process. Using this method, the quaternary and tertiary structural stabilities of well-behaved TTR sequences, wild-type (WT) TTR and the disease-associated variant V122I, were scrutinized. The V122I variant is linked to late onset familial amyloid cardiomyopathy, the most common familial TTR amyloid disease. V122I TTR exhibits a destabilized quaternary structure and a stable tertiary structure relative to those of WT TTR. Three other variants of TTR were also examined, L55P, V30M, and A25T TTR. The L55P mutation is associated with the most aggressive familial TTR amyloid disease. L55P TTR has a complicated denaturation pathway that includes dimers and trimers, so globally fitting its concentration-dependent urea denaturation data yielded error-laden estimates of stability parameters. Nevertheless, it is clear that L55P TTR is substantially less stable than WT TTR, primarily because its tertiary structure is unstable, although its quaternary structure is destabilized as well. V30M is the most common mutation associated with neuropathic forms of TTR amyloid disease. V30M TTR is certainly destabilized relative to WT TTR, but like L55P TTR, it has a complex denaturation pathway that cannot be fit to the aforementioned two-step denaturation model. Literature data suggest that V30M TTR has stable quaternary structure but unstable tertiary structure. The A25T mutant, associated with central nervous system amyloidosis, is highly aggregation-prone and exhibits drastically reduced quaternary and tertiary structural stabilities. The observed differences in stability among the disease-associated TTR variants highlight the complexity and heterogeneity of TTR amyloid disease, an observation that has important implications for the treatment of these maladies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537267      PMCID: PMC2667099          DOI: 10.1021/bi800636q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  48 in total

Review 1.  The genetics of the amyloidoses.

Authors:  J N Buxbaum; C E Tagoe
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

2.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.

Authors:  X Jiang; C S Smith; H M Petrassi; P Hammarström; J T White; J C Sacchettini; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

3.  Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.

Authors:  V L Shnyrov; E Villar; G G Zhadan; J M Sanchez-Ruiz; A Quintas; M J Saraiva; R M Brito
Journal:  Biophys Chem       Date:  2000-12-15       Impact factor: 2.352

4.  Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.

Authors:  A Quintas; D C Vaz; I Cardoso; M J Saraiva; R M Brito
Journal:  J Biol Chem       Date:  2001-04-16       Impact factor: 5.157

5.  Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins.

Authors:  F Schneider; P Hammarström; J W Kelly
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

6.  Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.

Authors:  P Hammarström; X Jiang; S Deechongkit; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

7.  Trans-suppression of misfolding in an amyloid disease.

Authors:  P Hammarström; F Schneider; J W Kelly
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

8.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin.

Authors:  A Hörnberg; T Eneqvist; A Olofsson; E Lundgren; A E Sauer-Eriksson
Journal:  J Mol Biol       Date:  2000-09-22       Impact factor: 5.469

9.  Equilibrium folding of dimeric class mu glutathione transferases involves a stable monomeric intermediate.

Authors:  J A Hornby; J K Luo; J M Stevens; L A Wallace; W Kaplan; R N Armstrong; H W Dirr
Journal:  Biochemistry       Date:  2000-10-10       Impact factor: 3.162

10.  Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-12-21       Impact factor: 7.446

View more
  52 in total

1.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

2.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 3.  Proteostasis strategies for restoring alpha1-antitrypsin deficiency.

Authors:  Marion Bouchecareilh; Juliana J Conkright; William E Balch
Journal:  Proc Am Thorac Soc       Date:  2010-11

4.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

5.  Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.

Authors:  Lorena Saelices; Malgorzata Pokrzywa; Katarzyna Pawelek; David S Eisenberg
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

6.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

Review 7.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

8.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

9.  Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses.

Authors:  Laura Cendron; Antonio Trovato; Flavio Seno; Claudia Folli; Beatrice Alfieri; Giuseppe Zanotti; Rodolfo Berni
Journal:  J Biol Chem       Date:  2009-07-14       Impact factor: 5.157

10.  Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.

Authors:  Teresa Mairal; Joan Nieto; Marta Pinto; Maria Rosário Almeida; Luis Gales; Alfredo Ballesteros; José Barluenga; Juan J Pérez; Jesús T Vázquez; Nuria B Centeno; Maria Joao Saraiva; Ana M Damas; Antoni Planas; Gemma Arsequell; Gregorio Valencia
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.